First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

NCT05271916 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Dacomitinib+Anlotinib
DRUG: Dacomitinib

Sponsor

Shanghai Chest Hospital